KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Long-Term Investments (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Long-Term Investments for 9 consecutive years, with $61.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments rose 200.96% year-over-year to $61.2 million, compared with a TTM value of $61.2 million through Dec 2025, up 200.96%, and an annual FY2025 reading of $61.2 million, up 200.96% over the prior year.
  • Long-Term Investments was $61.2 million for Q4 2025 at Biocryst Pharmaceuticals, up from $39.7 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $64.3 million in Q2 2024 and bottomed at $3.4 million in Q1 2023.
  • Average Long-Term Investments over 3 years is $26.9 million, with a median of $20.3 million recorded in 2024.
  • The sharpest move saw Long-Term Investments surged 1766.97% in 2024, then plummeted 84.29% in 2025.
  • Year by year, Long-Term Investments stood at $3.4 million in 2023, then skyrocketed by 489.93% to $20.3 million in 2024, then skyrocketed by 200.96% to $61.2 million in 2025.
  • Business Quant data shows Long-Term Investments for BCRX at $61.2 million in Q4 2025, $39.7 million in Q3 2025, and $10.1 million in Q2 2025.